Zoetis Sees Unusually Large Options Volume (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) was the target of unusually large options trading on Monday. Stock traders bought 8,095 call options on the stock. This represents an increase of approximately 59% compared to the typical daily volume of 5,087 call options.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of the stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Prosperity Bancshares Inc acquired a new stake in Zoetis during the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $28,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $30,000. Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Finally, Elyxium Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Stifel Nicolaus dropped their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. HSBC reduced their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Citigroup dropped their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Finally, Barclays cut their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $120.83.

Zoetis Price Performance

Shares of ZTS opened at $76.17 on Tuesday. The firm has a market cap of $31.93 billion, a price-to-earnings ratio of 12.63, a PEG ratio of 1.19 and a beta of 0.75. The stock has a 50 day moving average of $77.32 and a 200-day moving average of $105.54. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis has a 52 week low of $71.47 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the prior year, the company posted $1.48 earnings per share. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts forecast that Zoetis will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis saw unusual options activity, with traders buying 8,095 call options, about 59% above the average daily volume, suggesting some speculative bullish interest.
• Neutral Sentiment: Several law firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, the Schall Law Firm, Bronstein Gewirtz & Grossman LLC, DJS Law Group, and Bragar Eagel & Squire, reminded investors about a July 27 lead-plaintiff deadline in an existing class action related to Zoetis securities purchased between January 14, 2025 and May 6, 2026. Article Title
• Negative Sentiment: The class-action campaign keeps attention on alleged securities-law violations, which can create legal uncertainty and pressure the stock until the case is resolved. Article Title

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.